---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-010890"
form_type: "8-K"
ticker: "ELDN"
cik: "0001404281"
company_name: "Eledon Pharmaceuticals, Inc."
filed_at: "2022-05-31T23:59:59+00:00"
generated_at: "2026-06-25T05:49:56.399415+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eledon reports positive Phase 2a topline results for tegoprubart in ALS patients

## Summary
- Tegoprubart met primary safety and tolerability endpoints; no drug-related serious adverse events observed.
- Dose-dependent target engagement at 4 and 8 mg/kg; anti-drug antibodies in <5% of samples, low titer.
- Pro-inflammatory ALS signature of 32 biomarkers identified; dose-dependent reduction in up to 23 biomarkers.
- Trend in slowing ALS progression (ALSFRS slope) vs. PRO-ACT database; study not powered for efficacy.
- Reduced biomarkers also associated with IgA nephropathy and kidney transplant rejection (IgA, C3, CXCL9, etc.).

## SEC filing metadata
- accession: 0000950170-22-010890
- form_type: 8-K
- ticker: ELDN
- cik: 0001404281
- company_name: Eledon Pharmaceuticals, Inc.
- filed_at: 2022-05-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404281/000095017022010890/0000950170-22-010890-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404281/000095017022010890/eldn-20220531.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-010890
- JSON: https://secwatch.observer/filing/0000950170-22-010890.json
- Plain text: https://secwatch.observer/filing/0000950170-22-010890.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.